Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT00431015 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
88
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Infinity Pharmaceuticals, Inc.